OBR Daily Commentary

forumImage

AbbVie Announces Topline Results from Two Phase 3 Studies Investigating Veliparib in Combination with Chemotherapy for the Treatment of Patients with Advanced or Metastatic Squamous Non-Small Cell Lung Cancer and Early-Stage Triple-Negative Breast Cancer

(AbbVie) Apr 19, 2017 - AbbVie, a global biopharmaceutical company, today announced that two Phase 3 studies evaluating veliparib, an investigational, oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor did not meet their primary endpoints.

Read Article arrow

H. Jack West, MD (Posted: April 20, 2017)

quotesThe failure of the phase 3 trial with veliparib combined with chemotherapy is disappointing and yet another reminder of the gulf between promising phase II data and proven benefit in a larger, multicenter phase III trial. This was a large and likely well-conducted study that asked an important question and provided a valuable but humbling answer. Despite recent successes with checkpoint inhibitors and some targeted therapies, it remains quite challenging to generate clinically significant improvements in outcomes in patients with lung cancer. In the future, trials will increasingly need to focus on more narrow populations as the treatment algorithms incorporate PD-L1 expression and more driver mutations with different standard treatment approaches. quotes

Add Comment 2 Comment
forumImage

Roche’s Alecensa Beats Pfizer’s Xalkori In Lung Cancer Trial

(PharmaTimes [UK]) Apr 10, 2017 - Roche has presented late-stage data showing that its Alecensa was superior to Pfizer’s Xalkori on progression-free survival in patients with a specific type of lung cancer.

Read Article arrow

H. Jack West, MD (Posted: April 10, 2017)

quotesIn the wake of the highly positive preceding phase II version of this trial in Japanese ALK-positive patients (J-ALEX), we debated whether these results were compelling enough to warrant a change in first line treatment of ALK-positive but ALK inhibitor-naive patients. While that remains debatable, many thoughtful observers of this space have favored waiting until we obtained results from the larger and more demographically/geographically diverse phase III ALEX trial of alectinib vs. crizotinib, which also studied the global standard dose of alectinib (600 mg PO BID) rather than a unique lower dosing (300 mg PO BID) studied in the Japanese only population. We need to see the data, and I hope and expect that will occur at ASCO 2017 (in either the lung cancer oral abstracts on 6/6/17 or, even better, as part of the Plenary program on 6/4/17). However, now knowing that this trial was positive, as we had expected, these results should be enough to shift alectinib to become the standard of care for first line treatment of advanced ALK-positive NSCLC in the coming months.quotes

Add Comment 1 Comment
forumImage

NCCN Updates Lung Cancer Guideline, Again

(Medscape Medical News) Mar 24, 2017 - It's only March, but the National Comprehensive Cancer Network (NCCN) has already issued five updates of its 2017 non–small cell lung cancer (NSCLC) guidelines, as clinical practice continues to rapidly change, according to presenters here at the group's annual meeting.

Read Article arrow

H. Jack West, MD (Posted: March 24, 2017)

quotesIt's striking that we've needed yet another revision of the NCCN guidelines in NSCLC, but this is a reflection of how rapid the progress has been in the field. Adding PD-L1 expression testing at initial workup, including revised indications for the second line use of the various PD-1 and PD-L1 inhibitors, and including data on the very clear positive results for osimertinib in T790M-positive acquires resistance after first line EGFR Takis -- these are all valuable additions. Whether frustrating or encouraging, additional revisions will likely follow in the coming months, as new data lead to further rapid evolution of our standards of care in advanced NSCLC.quotes

Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...